Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311407 | 0.85 | QDPR (0.74) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2227613 | 0.85 | QDPR (0.59) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30957975 | 0.82 | PDE4B (0.62) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL310046 | 0.82 | PDE4B (0.62) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15652563 | 0.81 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15651488 | 0.81 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL15653074 | 0.81 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL17076795 | 0.81 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13362111 | 0.81 | QDPR (0.55) | QDPRPDE4BPDE4APDE4CPDE4D | |
| SCHEMBL17197281 | 0.81 | QDPR (0.52) | QDPRPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | CARDURION PHARMACEUTICALS, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| EP-3600327-A1 | HETEROCYCLIC COMPOUND | Cardurion Pharmaceuticals, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | CARDURION PHARMACEUTICALS, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | US | disclosed |
| WO-2018183112-A1 | HETEROCYCLIC COMPOUND | CARDURION PHARMACEUTICALS, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11197858-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | QDPR 242/4885PDE4B 806/4885PDE4A 614/4885 |
| US-20180280389-A1 | HETEROCYCLIC COMPOUND | CALM1, CAMK2B, CAMK2G | QDPR 282/4885PDE4B 1265/4885PDE4A 1216/4885 |
| US-10543212-B2 | Substituted amines for treating cardiac diseases | TNNI3, CALM1, CAMK2G | QDPR 242/4885PDE4B 806/4885PDE4A 614/4885 |
| US-20200230137-A1 | SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES | TNNI3, CALM1, CAMK2G | QDPR 242/4885PDE4B 806/4885PDE4A 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.